MRI screening may identify high-risk pancreatic cancer
the ONA take:
MRI-based screening may be effective in identifying high-risk pancreatic cancer, according to a recent study published in JAMA Surgery.
Researchers led by Marco Del Chiaro, MD, PhD, of the Karolinska Institute in Stockholm looked at 40 patients (24 women, 16 men) who were at genetic risk of developing pancreatic cancer in order to determine short-term results of a MRI-based screening program.
Median follow-up was 12.9 months, and MRI screening was repeated after one year if initial screening was negative or at six months if findings were unspecific.
The researchers were able to find pancreatic lesions in 16 patients – 40 percent – with 14 who had intraductal papillary mucinous neoplasia and two who had pancreatic ductal adenocarcinoma.
“An MRI-based protocol for the surveillance of individuals at risk for developing pancreatic cancer seems to detect cancer or premalignant lesions with good accuracy,” the authors concluded. “The exclusive use of MRI can reduce costs, increase availability and guarantee the safety of the individuals under surveillance compared with protocols that are based on more aggressive methods.”
However, the authors emphasize that their study did not allow for evaluation of efficacy as single-screening modality, due to the small patient sample.
MRI-based screening may be effective in identifying high-risk pancreatic cancer.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|